BioNTech SE
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- BioNTech SE (BNTX) is a biotechnology company focused on developing and commercializing immunotherapies for cancer and infectious diseases. The company offers a broad portfolio of products and services, including mRNA-based therapeutics and vaccines such as Comirnaty, its COVID-19 vaccine developed in partnership with Pfizer; individualized neoantigen-specific immunotherapies under the BioNTech's FixVac and iNeST platforms; antibody-drug conjugates; small molecule immunomodulators; and cell therapies targeting solid tumors and hematological malignancies; as well as oncology pipeline candidates like BNT327 (a PD-L1/VEGF bispecific antibody) and BNT116 (a next-generation FixVac for lung cancer). BioNTech operates primarily in the biopharmaceutical industry, serving global patient populations through clinical trials, regulatory approvals, and commercial distribution in over 30 countries across North America, Europe, Asia-Pacific, and emerging markets. Founded in 2008 and headquartered in Mainz, Germany, the company maintains subsidiaries worldwide, including in the United States, the United Kingdom, and China, with no parent company. Recent developments include the European Medicines Agency's approval in 2024 for BNT116 as the first mRNA-based lung cancer therapeutic; a multi-billion-dollar expansion of its manufacturing facilities in Rwanda and Australia announced in early 2025 to enhance global vaccine production capacity; deepened strategic alliances with Pfizer for next-generation COVID-19 vaccines and with Genentech for bispecific antibody development; and a $760 million funding round in late 2024 to advance its oncology pipeline amid robust Phase 3 trial progress.
BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026
BioNTech SE Sponsored ADR $BNTX Shares Sold by Baader Bank Aktiengesellschaft
Amova Asset Management Americas Inc. Invests $6.91 Million in BioNTech SE Sponsored ADR $BNTX
Cathie Wood's Ark Invest Sold $7.4 Million of BioNTech Stock
2 Dirt Cheap Dividend Stocks to Buy With $1,000 Right Now
BioNTech held buyer talks over four German sites set to close, Handelsblatt reports
Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO
Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study
Bristol Myers Showcases Data on MM and NSCLC Drugs at ASCO
Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally
BioNTech Announces New ADS Repurchase Program
BioNTech Q3 Earnings Review: Getting Into The Weeds With Bewildering Oncology Plans
Germany says vaccine supply secure despite BioNTech production loss
BioNTech SE (BNTX) Q1 2026 Earnings Call Transcript
BioNTech Slides As Vaccine Sales Drop, Restructuring Plan Takes Shape
BioNTech to Close Sites, Cut Quarter of Workforce in Savings Push